168047-35-6

Upstream product

• 168045-48-5 ethyl 2-<2,6-diaza-6-<(4-nitrophenyl)carbonyl>-3-oxobicyclo<5.4.0>undeca-1(7),8,10-trien-2-yl>acetate 
• 168048-37-1 ethyl 2-<6-<(4-aminophenyl)carbonyl>-2,6-diaza-3-oxobicyclo<5.4.0>undeca-1(7),8,10-trien-2-yl>acetate 
• 168045-47-4 2,6-diaza-6-<(4-nitrophenyl)carbonyl>bicyclo<5.4.0>undeca-1(7),8,10-trien-3-one 
• 226577-16-8 4,4-dimethyl-2-(3'-methyl-[1,1'-biphenyl]-2-yl)-4,5-dihydrooxazole 
• 122-04-3 4-nitro-benzoyl chloride 
• 107412-71-5 3'-methyl-[1,1'-biphenyl]-2-carboxylic acid 
• 591-17-3 meta-bromotoluene 
• 5755-07-7 2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one 
• 57598-33-1 2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 168047-98-1 1-Ethoxycarbonylmethyl-5-{4-[2-(3-methylphenyl)benzoylamino]benzoyl}-1,3,4,5-tetrahydro-1,5-benzodiazepin-2(2H)-one 

Relevant academic research and scientific papers

Synthesis and characterization of orally active nonpeptide vasopressin V2 receptor antagonists

The present study was undertaken to evaluate whether a novel series of 2,6-diaza-5-oxobicyclo[5.4.0]undeca-1(7),8,10-triene derivatives exhibited antagonistic activity for vasopressin V1 and V2 receptors. Most of these compounds were